• About Us

    Vitruvian Networks was co-founded by General Electric and the Mayo Clinic to solve key challenges in the commercialization and delivery of cell and gene therapies.


    Through our solutions and expertise, our mission is to enable high quality personalized cell therapies for more patients.

  • Leadership

    Amy DuRoss

    Chief Executive Officer

    Before co-founding Vitruvian Networks, Amy focused on healthcare new business creation for GE Ventures/ healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California’s $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.

    Heidi M. Hagen

    Chief Strategy Officer

    Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vitruvian Networks. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.

    Razmik Abnous

    Chief Technology Officer

    Razmik is a leading Business Software Executive. He is currently CTO and Co-founder for Vitruvian Networks. He was former CTO for EMC Documentum product family, leading Enterprise Content Management platform and solutions for Fortune 5000. Razmik was one of the original designers of Documentum platform. He was a founding member of Documentum team and helped grow it to become a leading force in Enterprise Content Management industry with an IPO in 1996 and eventual acquisition by EMC in 2003 for $1.7 Billion. Razmik is author of several patents and coauthor of several technical books. He is also investor and advisors to multiple high tech companies.

    Malek Faham, M.D., Ph.D.

    Chief Science Officer

    Dr. Malek Faham is Chief Scientific Officer and Co-founder of Vitruvian Networks. He was formerly co-founder and CSO of Sequenta Inc, where he led technology development, scientific direction, clinical validation, and operation from the initial vision in 2008 of the potential of immune receptor repertoire sequencing to the company’s acquisition in 2015 by Adaptive Biotechnologies. Previously, Dr. Faham co-founded Parallele Bioscience, Inc. in 2001 and served as its Director for Research until its acquisition by Affymetrix in 2005. He then served as VP of Oncology Technology Research at Affymetrix until 2008. He has published more than 50 peer-reviewed articles and has over 100 issued and pending patents. Dr. Faham received his MD, Ph.D. in biochemistry and human genetics and Psychiatry residency training from University of California San Francisco, and had his post doctoral training with Professor Ronald W. Davis in the Stanford Genome Technology Center.